Recently, the PROfound trial found that olaparib was somewhat effective in cases of advanced PC with HRD (BRCA1, BRCA2 or ATM) [14], as observed with our two patients with BRCA2 inactivation and partial and complete response to olaparib. This evidence concerns the gene BRCA1 and pachyonychia congenita.